Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment

Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment covers the entire spectrum of clinical drug therapy for adults, elderly adults, pregnant and nursing women, and children. Drugs are listed alphabetically, for quick navigation, and each drug entry includes name, molecular structure, dosing, pharmacological actions, indications and clinical applications, side effects and adverse/allergic reactions, and drug interactions. In the front are tables listing the chapters where each drug is discussed and the common disorders for which each is used. Color drug plates in the front help with rapid recognition of all major drugs.

Alphabetical listing of drugs for quick and easy navigation
Chapter on psychoactive herbs and medications
Color photo gallery of drugs in front to help providers and patients identify medications rapidly
Drug tables in front

Benjamin J Sadock MD
Menas S. Gregory Professor of Psychiatry, New York University School of Medicine; Attending Psychiatrist, Tisch Hospital; Attending Psychiatrist, Bellevue Hospital Center; Honorary Medical Staff, Lenox Hill Hospital, New York, NY


Virginia A Sadock MD
Professor of Psychiatry, Department of Psychiatry, New York University School of Medicine; Attending Psychiatrist, Tisch Hospital; Attending Psychiatrist, Bellevue Hospital Center, New York, NY


Norman Sussman MD
Professor of Psychiatry, New York University School of Medicine; Director of Psychopharmacology Research and Consultation Service, Bellevue Hospital Center, New York, NY

ContentsPreface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix 1. General Principles of Psychopharmacology . . . . . . . . . . . . . . . . . . . . . . . . . 1 2. α2-Adrenergic Receptor Agonists, α1-Adrenergic Receptor Antagonists: Clonidine, Guanfacine, Minipress and Yohimbine. . . . . . . . . . . . . . . . . . . . 25 3. β-Adrenergic Receptor Antagonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 4. Anticholinergics and Amantadine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 5. Anticonvulsants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 6. Antihistamines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 7. Barbiturates and Similarly Acting Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 8. Benzodiazepines and Drugs Acting on Benzodiazepine Receptors . . . . . 68 9. Bupropion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 10. Buspirone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 11. Calcium Channel Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 12. Carbamazepine and Oxcarbazepine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 13. Cholinesterase Inhibitors and Memantine . . . . . . . . . . . . . . . . . . . . . . . . . . . 101 14. Disulfiram and Acamprosate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 15. Dopamine Receptor Agonists and Precursors . . . . . . . . . . . . . . . . . . . . . . . . 113 16. Dopamine Receptor Antagonists (First Generation Antipsychotics) . . . . 118 17. Lamotrigine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137 18. Lithium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 19. Melatonin Agonists: Ramelton and Melatonin . . . . . . . . . . . . . . . . . . . . . . . 157 20. Mirtazapine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 21. Monoamine Oxidase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164 22. Nefazodone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171 23. Opioid Receptor Agonists: Methadone and Buprenorphine . . . . . . . . . . . 174 24. Opioid Receptor Antagonists: Naltrexone, Nalmefene, and Naloxone . . 181 25. Phosphodiesterase-5 Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188 26. Selective Serotonin–Norepinephrine Reuptake Inhibitors . . . . . . . . . . . . . 193 27. Selective Serotonin Reuptake Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200 28. Serotonin–Dopamine Antagonists and Similarly Acting Drugs (Second Generation or Atypical Antipsychotics) . . . . . . . . . . . . . . . . . . . . . 217 29. Sympathomimetics and Related Drugs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238 30. Thyroid Hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248 31. Trazodone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251 32. Tricyclics and Tetracyclics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255 33. Valproate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266 34. Nutritional Supplements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274 35. Intoxication and Overdose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288 Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299 About the Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315